Adverum Biotechnologies Inc (ADVM) - Total Liabilities
Based on the latest financial reports, Adverum Biotechnologies Inc (ADVM) has total liabilities worth $128.05 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ADVM shareholders equity momentum to track the company's year-over-year net asset growth rate.
Adverum Biotechnologies Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Adverum Biotechnologies Inc's total liabilities have evolved over time, based on quarterly financial data. See ADVM free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Adverum Biotechnologies Inc Competitors by Total Liabilities
The table below lists competitors of Adverum Biotechnologies Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GSD Holding AS
IS:GSDHO
|
Turkey | TL6.03 Billion |
|
Loop Telecommunication International Inc
TW:3025
|
Taiwan | NT$399.52 Million |
|
GEA Grenobl. Elect.
PA:GEA
|
France | €16.51 Million |
|
Caturkarda Depo Bangunan PT Tbk
JK:DEPO
|
Indonesia | Rp990.41 Billion |
|
Cheil Electric Wiring Devices Co. Ltd.
KQ:199820
|
Korea | ₩77.55 Billion |
|
Ampire Co Ltd
TWO:8049
|
Taiwan | NT$336.28 Million |
|
Roots Corp
TO:ROOT
|
Canada | CA$159.59 Million |
|
Cosmax Nbt Inc
KQ:222040
|
Korea | ₩242.96 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Adverum Biotechnologies Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ADVM market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Adverum Biotechnologies Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Adverum Biotechnologies Inc (2012–2024)
The table below shows the annual total liabilities of Adverum Biotechnologies Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $109.13 Million | +23.24% |
| 2023-12-31 | $88.55 Million | -30.20% |
| 2022-12-31 | $126.85 Million | +2.68% |
| 2021-12-31 | $123.54 Million | +156.20% |
| 2020-12-31 | $48.22 Million | +0.94% |
| 2019-12-31 | $47.77 Million | +287.49% |
| 2018-12-31 | $12.33 Million | -31.04% |
| 2017-12-31 | $17.88 Million | -5.83% |
| 2016-12-31 | $18.98 Million | +61.87% |
| 2015-12-31 | $11.73 Million | -5.60% |
| 2014-12-31 | $12.42 Million | +853.42% |
| 2013-12-31 | $1.30 Million | -5.78% |
| 2012-12-31 | $1.38 Million | -- |
About Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is … Read more